Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least double-vaccinated patients with inflammatory rheumatic diseases (IRDs).
METHODS: Data from the physician-reported German COVID-19-IRD registry collected between February 2021 and July 2022 were analysed. SARS-CoV-2 cases were stratified according to patients' vaccination status as being not vaccinated, double-vaccinated or triple-vaccinated prior to SARS-CoV-2 infection and descriptively compared. Independent associations between demographic and disease features and outcome of breakthrough infections were estimated by multivariable logistic regression.
RESULTS: In total, 2314 cases were included in the analysis (unvaccinated n=923, double-vaccinated n=551, triple-vaccinated n=803, quadruple-vaccinated n=37). SARS-CoV-2 infections occurred after a median of 151 (range 14-347) days in patients being double-vaccinated, and after 88 (range 14-270) days in those with a third vaccination. Hospitalisation was required in 15% of unvaccinated, 8% of double-vaccinated and 3% of triple-vaccinated/quadruple-vaccinated patients (p<0.001). Mortality was 2% in unvaccinated, 1.8% in the double-vaccinated and 0.6% in triple-vaccinated patients. Compared with unvaccinated patients, double-vaccinated (OR 0.43, 95% CI 0.29 to 0.62) and triple-vaccinated (OR 0.13, 95% CI 0.08 to 0.21) patients showed a significant lower risk of COVID-19-related hospitalisation. Using multivariable analysis, the third vaccination was significantly associated with a lower risk for COVID-19-related death (OR 0.26; 95% CI 0.01 to 0.73).
CONCLUSIONS: Our cross-sectional data of COVID-19 infections in patients with IRD showed a significant reduction of hospitalisation due to infection in double-vaccinated or triple-vaccinated patients compared with those without vaccination and even a significant reduction of COVID-19-related deaths in triple-vaccinated patients. These data strongly support the beneficial effect of COVID-19 vaccination in patients with IRD.
TRIAL REGISTRATION NUMBER: EuDRACT 2020-001958-21.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
RMD open - 9(2023), 2 vom: 17. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hasseli, Rebecca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic agents |
|---|
| Anmerkungen: |
Date Completed 19.04.2023 Date Revised 21.04.2023 published: Print EudraCT: 2020-001958-21 Citation Status MEDLINE |
|---|
| doi: |
10.1136/rmdopen-2023-002998 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355729202 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355729202 | ||
| 003 | DE-627 | ||
| 005 | 20231226064946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/rmdopen-2023-002998 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355729202 | ||
| 035 | |a (NLM)37068915 | ||
| 035 | |a (PII)e002998 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hasseli, Rebecca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2023 | ||
| 500 | |a Date Revised 21.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a EudraCT: 2020-001958-21 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: To analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least double-vaccinated patients with inflammatory rheumatic diseases (IRDs) | ||
| 520 | |a METHODS: Data from the physician-reported German COVID-19-IRD registry collected between February 2021 and July 2022 were analysed. SARS-CoV-2 cases were stratified according to patients' vaccination status as being not vaccinated, double-vaccinated or triple-vaccinated prior to SARS-CoV-2 infection and descriptively compared. Independent associations between demographic and disease features and outcome of breakthrough infections were estimated by multivariable logistic regression | ||
| 520 | |a RESULTS: In total, 2314 cases were included in the analysis (unvaccinated n=923, double-vaccinated n=551, triple-vaccinated n=803, quadruple-vaccinated n=37). SARS-CoV-2 infections occurred after a median of 151 (range 14-347) days in patients being double-vaccinated, and after 88 (range 14-270) days in those with a third vaccination. Hospitalisation was required in 15% of unvaccinated, 8% of double-vaccinated and 3% of triple-vaccinated/quadruple-vaccinated patients (p<0.001). Mortality was 2% in unvaccinated, 1.8% in the double-vaccinated and 0.6% in triple-vaccinated patients. Compared with unvaccinated patients, double-vaccinated (OR 0.43, 95% CI 0.29 to 0.62) and triple-vaccinated (OR 0.13, 95% CI 0.08 to 0.21) patients showed a significant lower risk of COVID-19-related hospitalisation. Using multivariable analysis, the third vaccination was significantly associated with a lower risk for COVID-19-related death (OR 0.26; 95% CI 0.01 to 0.73) | ||
| 520 | |a CONCLUSIONS: Our cross-sectional data of COVID-19 infections in patients with IRD showed a significant reduction of hospitalisation due to infection in double-vaccinated or triple-vaccinated patients compared with those without vaccination and even a significant reduction of COVID-19-related deaths in triple-vaccinated patients. These data strongly support the beneficial effect of COVID-19 vaccination in patients with IRD | ||
| 520 | |a TRIAL REGISTRATION NUMBER: EuDRACT 2020-001958-21 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antirheumatic agents | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Richter, Jutta G |e verfasserin |4 aut | |
| 700 | 1 | |a Hoyer, Bimba Franziska |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenz, Hanns-Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeil, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Regierer, Anne Constanze |e verfasserin |4 aut | |
| 700 | 1 | |a Schmeiser, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Strangfeld, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Voll, Reinhard E |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Reckert, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Gräßler, Anett |e verfasserin |4 aut | |
| 700 | 1 | |a Saar, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Kapelle, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Backhaus, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Blank, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Henes, Joerg |e verfasserin |4 aut | |
| 700 | 1 | |a Osiek, Silke |e verfasserin |4 aut | |
| 700 | 1 | |a Knothe, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Hoese, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Brandt-Jürgens, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Maltzahn, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Specker, Christof |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Ladner, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze-Koops, Hendrik |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 task force of the German Society of Rheumatology collaborators |e verfasserin |4 aut | |
| 700 | 0 | |a COVID19-Rheuma.de collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Albach, Fredrik |e investigator |4 oth | |
| 700 | 1 | |a Alberding, Annette |e investigator |4 oth | |
| 700 | 1 | |a Alexander, Tobias |e investigator |4 oth | |
| 700 | 1 | |a Alten, Rieke |e investigator |4 oth | |
| 700 | 1 | |a Aman, Susanne |e investigator |4 oth | |
| 700 | 1 | |a Amberger, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Amberger, Michaela |e investigator |4 oth | |
| 700 | 1 | |a Andermann, Bianka |e investigator |4 oth | |
| 700 | 1 | |a Anders, Nils |e investigator |4 oth | |
| 700 | 1 | |a Andreica, Ioana |e investigator |4 oth | |
| 700 | 1 | |a Andresen, Jan |e investigator |4 oth | |
| 700 | 1 | |a Andriopoulos, Nikolaos |e investigator |4 oth | |
| 700 | 1 | |a Arauj, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Aries, Peer |e investigator |4 oth | |
| 700 | 1 | |a Aringer, Martin |e investigator |4 oth | |
| 700 | 1 | |a Arndt, Uta |e investigator |4 oth | |
| 700 | 1 | |a Avemarg, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Baerwald, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Bärlin, Erich |e investigator |4 oth | |
| 700 | 1 | |a Bartholomä, Nora |e investigator |4 oth | |
| 700 | 1 | |a Bastian, Hans |e investigator |4 oth | |
| 700 | 1 | |a Bäuerle, Michael |e investigator |4 oth | |
| 700 | 1 | |a Bauhammer, Jutta |e investigator |4 oth | |
| 700 | 1 | |a Baumann, Christine |e investigator |4 oth | |
| 700 | 1 | |a Becker, Klaus |e investigator |4 oth | |
| 700 | 1 | |a Becker, Heidemarie |e investigator |4 oth | |
| 700 | 1 | |a Bellm, Michaela |e investigator |4 oth | |
| 700 | 1 | |a Berger, Sylvia |e investigator |4 oth | |
| 700 | 1 | |a Berghofen, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Birkner, Gerhard |e investigator |4 oth | |
| 700 | 1 | |a Blendea, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Bloching, Hans |e investigator |4 oth | |
| 700 | 1 | |a Blötz, Sebastian |e investigator |4 oth | |
| 700 | 1 | |a Blum, Christian |e investigator |4 oth | |
| 700 | 1 | |a Boeddeker, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Bogner, Susanne |e investigator |4 oth | |
| 700 | 1 | |a Bohl-Bühler, Martin |e investigator |4 oth | |
| 700 | 1 | |a Bohnen, Lara |e investigator |4 oth | |
| 700 | 1 | |a Bösenberg, Ilka |e investigator |4 oth | |
| 700 | 1 | |a Böttcher, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Braun, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Braun, Diana |e investigator |4 oth | |
| 700 | 1 | |a Braunisch, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Bremer, Jan Philipp |e investigator |4 oth | |
| 700 | 1 | |a Broll, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Bruckner, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Brumberger, Veronika |e investigator |4 oth | |
| 700 | 1 | |a Brzank, Martin |e investigator |4 oth | |
| 700 | 1 | |a Büllesfeld, Sahra |e investigator |4 oth | |
| 700 | 1 | |a Burger, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Chehab, Gamal |e investigator |4 oth | |
| 700 | 1 | |a Christenn, Michaela |e investigator |4 oth | |
| 700 | 1 | |a Claußnitzer, Anne |e investigator |4 oth | |
| 700 | 1 | |a Groot, Kirsten de |e investigator |4 oth | |
| 700 | 1 | |a Decker, Elvira |e investigator |4 oth | |
| 700 | 1 | |a Demtröder, Frank |e investigator |4 oth | |
| 700 | 1 | |a Detert, Jacqueline |e investigator |4 oth | |
| 700 | 1 | |a Dörfler, Rainer |e investigator |4 oth | |
| 700 | 1 | |a Drexler, Elke |e investigator |4 oth | |
| 700 | 1 | |a Dudics, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Edelmann, Edmund |e investigator |4 oth | |
| 700 | 1 | |a Eder, Roman |e investigator |4 oth | |
| 700 | 1 | |a Eisterhues, Christina |e investigator |4 oth | |
| 700 | 1 | |a Engel, Joachim Michael |e investigator |4 oth | |
| 700 | 1 | |a Erbslöh-Möller, Brigitte |e investigator |4 oth | |
| 700 | 1 | |a Feine, Miriam |e investigator |4 oth | |
| 700 | 1 | |a Ferdinan, Samantha |e investigator |4 oth | |
| 700 | 1 | |a Feuchtenberger, Martin |e investigator |4 oth | |
| 700 | 1 | |a Fiehn, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Finzel, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Fischer-Betz, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Fleck, Martin |e investigator |4 oth | |
| 700 | 1 | |a Franke, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Freudenberg, Stefanie |e investigator |4 oth | |
| 700 | 1 | |a Fräbel, Christian |e investigator |4 oth | |
| 700 | 1 | |a Fuchs, Petra |e investigator |4 oth | |
| 700 | 1 | |a Gaissmaier, Regina |e investigator |4 oth | |
| 700 | 1 | |a Gao, Ino |e investigator |4 oth | |
| 700 | 1 | |a Gardt, Oliver |e investigator |4 oth | |
| 700 | 1 | |a Gauler, Georg |e investigator |4 oth | |
| 700 | 1 | |a Geißler, Katrin |e investigator |4 oth | |
| 700 | 1 | |a Gente, Karolina |e investigator |4 oth | |
| 700 | 1 | |a Georgi, Joachim |e investigator |4 oth | |
| 700 | 1 | |a Gilly, Jasmin |e investigator |4 oth | |
| 700 | 1 | |a Gkanatsas, Yannik |e investigator |4 oth | |
| 700 | 1 | |a Glaser, Cornelia |e investigator |4 oth | |
| 700 | 1 | |a Schwister, Agnes Gniezinski- |e investigator |4 oth | |
| 700 | 1 | |a Gold, Rahel |e investigator |4 oth | |
| 700 | 1 | |a Görl, Norman |e investigator |4 oth | |
| 700 | 1 | |a Görlitz, Ralf |e investigator |4 oth | |
| 700 | 1 | |a Göttl, Karl-Heinz |e investigator |4 oth | |
| 700 | 1 | |a Göttle, Beate |e investigator |4 oth | |
| 700 | 1 | |a Bouyer, Ricardo Grieshaber |e investigator |4 oth | |
| 700 | 1 | |a Grothues, Gisela |e investigator |4 oth | |
| 700 | 1 | |a Grünke, Mathias |e investigator |4 oth | |
| 700 | 1 | |a Günther, Janine |e investigator |4 oth | |
| 700 | 1 | |a Günther, Florian |e investigator |4 oth | |
| 700 | 1 | |a Haag, Mirjam |e investigator |4 oth | |
| 700 | 1 | |a Haas, Linda |e investigator |4 oth | |
| 700 | 1 | |a Haas-Wöhrle, Anna |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t RMD open |d 2015 |g 9(2023), 2 vom: 17. Apr. |w (DE-627)NLM254089658 |x 2056-5933 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:2 |g day:17 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/rmdopen-2023-002998 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 2 |b 17 |c 04 | ||